Data gathered: November 21
AI Stock Analysis - Ardelyx (ARDX)
Analysis generated November 19, 2024. Powered by Chat GPT.
Ardelyx is a biopharmaceutical company that focuses on the development and commercialization of small molecule medicines to treat cardiorenal and gastrointestinal diseases. As a specialty pharmaceutical player, Ardelyx’s lead programs and developmental focuses place it in promising yet competitive market segments. The company's current flagship product continues to attract investor interest and market speculation.
Stock Alerts - Ardelyx (ARDX)
 |
Ardelyx | November 19 Price is down by -5.4% in the last 24h. |
|
Ardelyx | November 15 Price is up by 5.9% in the last 24h. |
|
Ardelyx | November 14 Price is up by 5.1% in the last 24h. |
|
Ardelyx | November 12 Price is down by -5% in the last 24h. |
Alternative Data for Ardelyx
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 30 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 26,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| Patents | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 24 | Sign up | Sign up | Sign up |
| Facebook Followers | 222 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 40 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,293 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,773 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 364 | Sign up | Sign up | Sign up |
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
| Price | $4.96 |
| Target Price | Sign up |
| Volume | 446,750 |
| Market Cap | $1.13B |
| Year Range | $4.5 - $9.31 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Ardelyx, Inc. (NASDAQ:ARDX) Receives $10.42 Average PT from BrokeragesNovember 19 - ETF Daily News |
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNovember 19 - Finnhub |
|
 |
Ardelyx's Medicare Setback Casts Doubt On Long-Term ViabilityNovember 13 - SeekingAlpha |
|
Creative Planning Decreases Holdings in Ardelyx, Inc. (NASDAQ:ARDX)November 13 - ETF Daily News |
 |
Ardelyx Responds to District Court Decision Granting Motion to DismissNovember 8 - Yahoo |
|
Leerink Partnrs Reduces Earnings Estimates for ArdelyxNovember 6 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 98M | 81M | 18M | -810,000 | 2.2M | -0.003 |
| Q2 '24 | 73M | 74M | -870,000 | -16M | -13M | -0.070 |
| Q1 '24 | 44M | 60M | -16M | -27M | -24M | -0.110 |
| Q4 '23 | 33M | 54M | -20M | -29M | -26M | -0.120 |
| Q3 '23 | 55M | 41M | 14M | 6.6M | 8.9M | 0.030 |
Insider Transactions View All
| Rosenbaum David P. filed to sell 153,616 shares at $6.1. November 8 '24 |
| Rosenbaum David P. filed to sell 153,616 shares at $6. November 6 '24 |
| RAAB MICHAEL filed to sell 1,210,108 shares at $5.9. October 31 '24 |
| RAAB MICHAEL filed to sell 1,210,108 shares at $6. October 15 '24 |
| Rosenbaum David P. filed to sell 301,946 shares at $6.9. October 1 '24 |
Similar companies
Read more about Ardelyx (ARDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Ardelyx?
The Market Cap of Ardelyx is $1.13B.
What is the current stock price of Ardelyx?
Currently, the price of one share of Ardelyx stock is $4.96.
How can I analyze the ARDX stock price chart for investment decisions?
The ARDX stock price chart above provides a comprehensive visual representation of Ardelyx's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ardelyx shares. Our platform offers an up-to-date ARDX stock price chart, along with technical data analysis and alternative data insights.
Does ARDX offer dividends to its shareholders?
As of our latest update, Ardelyx (ARDX) does not offer dividends to its shareholders. Investors interested in Ardelyx should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ardelyx?
Some of the similar stocks of Ardelyx are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.